Premium
Treatment of myoclonic syndromes with paroxetine alone or combined with 5‐HTP
Author(s) -
Magnussen I.,
Mondrup K.,
Engbék F.,
Lademann A.,
Fine Olivarius B.
Publication year - 1982
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1982.tb04525.x
Subject(s) - paroxetine , myoclonus , carbidopa , 5 hydroxytryptophan , levodopa , reuptake inhibitor , medicine , pharmacology , anesthesia , serotonin , parkinson's disease , receptor , disease
Paroxetine is a specific presynaptic 5‐hydroxytryptamine (5‐HT) reuptake inhibitor which ameliorated posthypoxic intention myoclonus in 2 out of 3 patients, when given alone or in combination with L‐5‐hydroxytryptophan (5‐HTP) with carbidopa. The concentration of 5‐HT in the cerebrospinal fluid from 1 patient was only 3 nmol/l despite the presence of 600 nmol/l of 5‐HTP during steady state treatment with the amino acid and paroxetine. No effect of the combined medication was found in 2 patients disordered by palatal myoclonus.